BioCryst Pharmaceuticals’ BCRX stock was down almost 38% on Friday following its announcement of pausing enrolment in clinical studies for its pipeline candidate, BCX9930 BCX9930 is a BioCryst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback